Table 3. Secondary outcome of treatment discontinuation due to any reason.

Paroxetine
0.57 (0.15 to 4.12)	Nortriptyline
0.81 (0.21 to 1.87)	1.02 (0.24 to 2.83)	Placebo
2.38 (0.03 to 14.39)	3.12 (0.04 to 18.51)	0.32 (0.06 to 16.91)	Trazodone
0.32 (0.09 to 1.87)	0.41 (0.12 to 2.11)	0.54 (0.21 to 1.84)	0.18 (0.03 to 12.28)	Fluoxetine
0.04 (0.01 to 27.26)	0.05 (0.01 to 33.47)	0.07 (0.01 to 34.15)	0.02 (0.00 to 64.35)	0.10 (0.02 to 58.07)	Duloxetine
0.46 (0.05 to 1.63)	0.58 (0.06 to 2.32)	0.34 (0.11 to 1.74)	0.11 (0.02 to 10.03)	1.05 (0.12 to 4.04)	6.20 (0.01 to 39.79)	Sertraline
0.03 (0.01 to 2.94)	0.03 (0.01 to 6.15)	0.04 (0.01 to 5.59)	0.02 (0.00 to 16.57)	1.77 (0.01 to 11.07)	14.11 (0.00 to 79.58)	0.07 (0.01 to 17.71)	Imipramine
0.09 (0.02 to 1.23)	0.10 (0.02 to 1.69)	0.15 (0.04 to 1.38)	0.05 (0.01 to 6.47)	0.21 (0.04 to 2.96)	0.03 (0.01 to 18.81)	0.30 (0.06 to 4.25)	0.16 (0.02 to 43.48)	Citalopram
0.11 (0.03 to 0.85)	0.12 (0.03 to 1.48)	0.18 (0.05 to 1.18)	0.06 (0.01 to 6.20)	0.24 (0.06 to 2.68)	0.02 (0.01 to 30.86)	0.31 (0.07 to 4.60)	0.20 (0.03 to 37.01)	2.23 (0.10 to 12.18)	Doxepin

Drugs are reported in order of efficacy ranking, and outcomes are standardized odds ratios (ORs; 95% confidence intervals). ORs of less than 1 indicate that the treatment specified in the column is better than placebo. Bold results indicate statistical significance (P<0.05, network meta-analysis).